Phaseline

Companies › S.Biomedics

S.Biomedics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Neurology, Other; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell l
Neural precursor cell transplantation therapy
NCAM1Phase 1Spinal Cord Injury, AcuteOct 2028
Clusters of Autologous Dermal Fibroblasts (3D-F, FECS-DF)
Autologous dermal fibroblast cell therapy for dermal regeneration and wrinkle reduction
–Phase 1Crow's Feet–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04818203Clusters of Autologous Dermal Fibroblasts (3D-F, FECS-DF)Phase 1Crow's FeetOtherJul 2025
NCT04812431PSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell lPhase 1Spinal Cord Injury, AcuteNeurologyOct 2028

Targets

NCAM1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.